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Abstract. 
 
Myoblast transplantation has been exten-
sively studied as a gene complementation approach for 
genetic diseases such as Duchenne Muscular Dystro-
phy. This approach has been found capable of deliver-
ing dystrophin, the product missing in Duchenne Mus-
cular Dystrophy muscle, and leading to an increase of 
strength in the dystrophic muscle. This approach, how-
ever, has been hindered by numerous limitations, in-
cluding immunological problems, and low spread and 
poor survival of the injected myoblasts. We have inves-
tigated whether antiinflammatory treatment and use of 
different populations of skeletal muscle–derived cells 
may circumvent the poor survival of the injected myo-
blasts after implantation. We have observed that differ-
ent populations of muscle-derived cells can be isolated 
from skeletal muscle based on their desmin immunore-
activity and differentiation capacity. Moreover, these 
cells acted differently when injected into muscle: 95% 
of the injected cells in some populations died within
48 h, while others richer in desmin-positive cells sur-
vived entirely. Since pure myoblasts obtained from iso-
lated myofibers and myoblast cell lines also displayed a 
poor survival rate of the injected cells, we have con-
cluded that the differential survival of the populations 
of muscle-derived cells is not only attributable to their 
content in desmin-positive cells. We have observed that 
the origin of the myogenic cells may influence their sur-
vival in the injected muscle. Finally, we have observed 
that myoblasts genetically engineered to express an in-
hibitor of the inflammatory cytokine, IL-1, can improve 
the survival rate of the injected myoblasts. Our results 
suggest that selection of specific muscle-derived cell 
populations or the control of inflammation can be used 
as an approach to improve cell survival after both myo-
blast transplantation and the myoblast-mediated ex 
vivo
 
 
 
gene transfer approach.
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D
 
UCHENNE
 
 Muscular Dystrophy (DMD)
 
1
 
 is an inher-
ited muscle disease characterized by the absence
of dystrophin in the membrane-associated cyto-
skeleton of muscle fibers (Hoffman et al., 1987; Arahata et
al., 1989; Sugita et al., 1988; Zubryzcka-Gaarn et al., 1988).
Dystrophin is associated with a large oligomeric complex
of glycoproteins called dystrophin-associated proteins
(DAPs) that provide linkage to the extracellular matrix
(Ervasti and Campbell, 1991; Ibraghinov-Beskrovnaya et
al., 1992; Matsumara et al., 1992; Matsumara and Camp-
bell, 1994; Ozawa et al., 1995). The lack of dystrophin in
dystrophic muscle, as well as the subsequent absence of all
DAPs, disrupts the linkage between the subsarcolemmal
cytoskeleton and the extracellular matrix (Matsumara et
al., 1992; Matsumara and Campbell, 1994; Ozawa et al.,
1995), resulting in muscle fiber necrosis and progressive
muscle weakness (Watkins et al., 1988; Bonilla et al.,
1988; Menke and Jokush, 1991). The mdx mouse, an ani-
mal model for DMD, also lacks dystrophin and DAPs in
skeletal muscle fibers (Bulfield et al., 1984; Hoffman et
al., 1987; Sincinsky et al., 1989).
Transplantation of normal myoblasts into dystrophin-
deficient muscle can potentially create a reservoir of nor-
mal myoblasts capable of fusing with dystrophic muscle fi-
bers and restoring dystrophin (Partridge, 1991). Previous
experiments (Partridge et al., 1989; Alamedine et al., 1989;
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Morgan et al., 1990; Huard et al., 1991) showed that nor-
mal myoblasts fuse with dystrophic myoblasts to form hy-
brid myotubes expressing dystrophin, and transplantation
of normal myoblasts resulted in dystrophin expression at
the muscle fiber plasma membrane in the injected dystro-
phic muscle (mdx). The initial clinical trials of myoblast
transfer to DMD patients demonstrated transient restora-
tion of dystrophin-positive muscle fibers and an improve-
ment of muscle strength in the injected DMD patients
(Law et al., 1991; Huard et al., 1992
 
a
 
; Huard et al., 1992
 
b
 
;
Karpati et al., 1993; Gussoni et al., 1992; Gussoni et al.,
1997; Tremblay et al., 1993; Mendell et al., 1995). Al-
though other limitations like the low spread and poor sur-
vival rate of the injected myoblasts may not be excluded
(Huard et al., 1994
 
c
 
; Beauchamps et al., 1994; Fan et al.,
1996; Guerette et al., 1997; Tremblay et al., 1997; Merly et al.,
1998), the failure of myoblast transfer in these clinical tri-
als was at least partly related to immune rejection. This hy-
pothesis was supported by the detection of serum antibod-
ies against the injected cell antigens, such as dystrophin
and dystrophin-associated proteins, in some DMD pa-
tients after transplantation (Huard et al., 1992
 
b
 
). More-
over, prolonged efficacy of myoblast transplantation was
observed in immunodeficient nude and SCID mice
(Huard et al., 1994
 
a
 
; Huard et al., 1994
 
b
 
), as well as in
mice adequately immunosuppressed using FK-506 (Ki-
noshita et al., 1994).
Although recent effort has been focused on developing
gene therapy approaches to deliver genes to skeletal mus-
cle, it has also been hindered by some limitations. Intra-
muscular injection of naked or complexed DNA (lipo-
somes) carrying reporter genes or dystrophin constructs
has been relatively inefficient (Acsadi et al., 1991; Wolff
et al., 1992; Katsumi et al., 1994). Retroviral vectors are
capable of introducing truncated dystrophin to dystrophic
myoblasts
 
 
 
in vitro, but are incapable of efficiently trans-
ducing differentiated muscle cells such as myotubes and
myofibers because they require dividing cells for integra-
tion and expression (Dunckley et al., 1992; Dunckley et al.,
1993). While adenovirus (AV) appears to be a relatively
good vector for skeletal muscle cells, potential limitations
exist for the use of AV as a gene delivery vector to muscle,
i.e., the differential transducibility of myofibers through-
out muscle maturation, the immune rejection induced by
first-generation adenoviral vectors, and the high titer of vi-
ral recombinants often required for successful muscle
transduction (Quantin et al., 1992; Ragot et al., 1993; Vin-
cent et al., 1993; Smith et al., 1993; Acsadi et al., 1994
 
a
 
;
Acsadi et al., 1994
 
b; 
 
Acsadi et al.,
 
 
 
1996; Yang et al., 1994;
Engelhardt et al., 1994; Dai et al., 1995). Recent studies
with mutant AV vectors in which all viral genes were re-
moved suggest that these vectors may be able to circum-
vent the immunological problems related to viral antigens
(Kochanek et al., 1996; Kumar-Singh and Chamberlain,
1996; Haecker et al., 1996; Clemens et al., 1996). Further-
more, the replication-defective Herpes Simplex virus type
1 (HSV-1) vector has been found capable of infecting and
expressing a foreign reporter gene in muscle cells
 
 
 
in vitro
and in newborn myofibers
 
 
 
in vivo. Limitations to the use
of the first-generation HSV-1 vector for muscles include
inefficient transduction of mature myofibers, cytotoxicity,
and immune rejection (Huard et al., 1995; Huard et al.,
1996; Huard et al., 1997). More recently, recombinant ad-
eno-associated viral vectors have been used as gene deliv-
ery vehicles for skeletal muscle cells. Although a high effi-
ciency of gene transfer occurs in mature muscle, and a
long-term transgene expression of up to 18 mo has been
observed (Kessler et al., 1996; Xiao et al., 1996; Reed
Clark et al., 1997), the use of this viral vector remains lim-
ited in its application for DMD due to its restricted gene
insert capacity (
 
,
 
5 kb).
Through the combination of myoblast transplantation
and gene therapy, the ex vivo
 
 
 
gene transfer approach has
been investigated as a gene delivery approach to skeletal
muscle. It has been shown that isogenic myoblasts trans-
duced
 
 
 
in vitro
 
 
 
with adenovirus, retrovirus, and HSV-1
(Salvatori et al., 1993; Huard et al., 1994
 
c
 
; Rando and
Blau, 1994; Booth et al., 1997; van Deutekom et al., 1998
 
a
 
;
van Deutekom et al. 1998
 
b
 
) are capable of delivering re-
porter genes to skeletal muscle. We have recently evalu-
ated the feasibility of transferring full-length dystrophin
into mdx mice through myoblast-mediated ex vivo gene
transfer (Floyd et al., 1997; Floyd et al., 1998). We have in-
fected myoblasts incapable of producing dystrophin with
an adenoviral vector lacking all the viral genes, but carry-
ing the expression of full-length dystrophin and 
 
b
 
-galac-
tosidase (Kochanek et al., 1996). The isogenic primary
mdx myoblasts and immortalized mdx cell line, which
were both transduced with the adenoviral vector, have
been capable of expressing 
 
b
 
-galactosidase and full-length
dystrophin
 
 
 
in vitro. Subsequently, these transduced myo-
blasts have been injected into dystrophic mdx muscle, and
the injected cells have restored dystrophin and dystrophin-
associated proteins (Floyd et al., 1997; Floyd et al., 1998).
The
 
 
 
ex vivo procedure may possess some positive at-
tributes as a gene transfer strategy to skeletal muscle: the
approach can create a reservoir of myoblasts capable of
regenerating and restoring dystrophin to dystrophic mus-
cle. Furthermore, since one of the major barriers to the ap-
plication of gene therapy to skeletal muscle is the inability
of viral vectors to transduce mature myofibers efficiently,
we have recently investigated the ex vivo
 
 
 
technique as an
approach to circumvent the maturation-dependent viral
transduction of skeletal muscle. The efficiency in gene
transfer of the same number of viral particles (adenovirus,
retrovirus, and HSV-1) has been found superior when us-
ing the
 
 
 
ex vivo approach rather than the direct gene trans-
fer approach (Booth et al., 1997; Floyd et al., 1997; Floyd
et al., 1998). The
 
 
 
ex vivo approach could present an impor-
tant alternative treatment, particularly for DMD patients
over 10 yr of age whose myofibers become extremely inef-
ficient in regeneration and may be refractory to direct vi-
ral transduction.
Both the ex vivo procedure and the myoblast transfer
approach are limited by the poor survival of the injected
myoblasts. The aim of this study is to identify the causes of
the poor survival in order to eventually develop ap-
proaches to reduce early loss of injected myoblasts. We
have investigated whether antiinflammatory treatment
and different populations of skeletal muscle–derived cells
can help to circumvent this major hurdle facing the appli-
cation of cell and gene therapy to skeletal muscle. This
study should aid in the development of strategies to
achieve efficient gene delivery to skeletal muscle for in- 
Qu et al. 
 
Cell Survival and Myoblast Transfer Therapy
 
1259
 
herited diseases and treatment of inadequate and deficient
muscle healing after injuries.
 
Materials and Methods
 
Purification of Primary Myoblasts
 
Purification of the primary muscle–derived cells was performed using a
previously described protocol (Rando and Blau, 1994). The forelimbs and
the hindlimbs were removed from neonatal mdx mice, and the bone was
dissected. The remaining muscle mass was minced into a coarse slurry us-
ing razor blades. Cells were enzymatically dissociated by adding 0.2% col-
lagenase-type XI for 1 h at 37
 
8
 
C, dispase (grade II 240 ml) for 30 min, and
0.1% trypsin for 30 min. The muscle cell extract was preplated on col-
lagen-coated flasks. We isolated different populations of muscle-derived
cells based on the number of preplates performed on collagen-coated,
flasks. Preplate (PP) 1 represented a population of muscle-derived cells
that adhered in the first hour after isolation, PP2 in the next 2 h, PP3 in the
next 18 h, and the subsequent preplates were obtained at 24-h intervals
(PPs 4–6). The myogenic population in each flask was evaluated by
desmin staining and on differentiation ability when cultured in a fusion
medium. The proliferation medium was F10-Ham–supplemented with
20% FBS and 1% penicillin/streptomycin; the fusion medium was F10-
Ham supplemented with 2% FBS and 1% antibiotic solution (penicillin/
streptomycin). All the culture medium supplies were purchased through
Gibco Laboratories (Grand Island, NY). The different populations of
cells were infected with 
 
b
 
-galactosidase–expressing adenovirus. The aden-
ovirus, an E1–E3 deleted recombinant adenovirus kindly obtained
through Dr. I. Kovesdi (GeneVec Inc., Rockville, MD), had the 
 
b
 
-galac-
tosidase reporter gene under the control of the human cytomegalovirus
promoter and followed by the SV40 t-intron and polyadenylation signal.
The adenovirally transduced cells were transplanted into the hindlimb
muscle (gastrocnemius and soleus) of mdx mice, and were assayed for
their survival after implantation (see below).
 
Myoblasts Isolated from Single Viable Myofibers
 
Single muscle fibers were prepared from dissected extensor digitorum lon-
gus (EDL) muscle by enzymatic desegregation in 0.2% type 1 collagenase
(Sigma Chemical Co., St. Louis, MO) as previously described (Rosenblatt
et al., 1995; Feero et al., 1997). Isolated muscle fibers from 6-wk-old mice
were used for this project. After isolating 
 
z
 
200 myofibers per muscle, a
minimum of 5–10 myofibers per well were plated on 6-well plates coated
with 1 mg/ml Matrigel (Collaborative Biomedical Products, Bedford,
MA) in 2 ml DMEM containing 10% horse serum, 1% chick embryo ex-
tract, 2% 
 
l
 
-glutamine, and 1% penicillin/streptomycin (Gibco Laborato-
ries). The plates were placed in a 37
 
8
 
C, 5% CO
 
2
 
 incubator for several
days. The cells emerging from these myofibers were grown until conflu-
ence, assayed for desmin expression, transduced with adenovirus carrying
LacZ reporter gene expression, and tested for myoblast survival after im-
plantation following the protocol described below.
 
Immortalized Cell Line
 
We used an immortalized mdx cell line isolated from a transgenic animal
carrying a thermolabile SV40 T antigen under the control of an inducible
promoter (Morgan et al., 1994). The immortalized mdx cell line prolifer-
ated indefinitely under the permissive conditions of 33
 
8
 
C with gamma in-
terferon (proliferation medium; DMEM 
 
1
 
 20% FBS) and underwent nor-
mal differentiation at 37–39
 
8
 
C without gamma interferon (fusion medium;
DMEM 
 
1
 
 2% FBS). This myoblast cell line was assayed for desmin im-
munoreactivity and the ability to differentiate when cultivated in a fusion
medium. Subsequently, these cells were transduced with adenovirus carry-
ing LacZ reporter gene expression, and the survival of the injected myo-
blasts was analyzed as described below.
 
Myoblasts Engineered to Express
Antiinflammatory Substance
 
The mdx myoblast cell line was used for engineering the myoblasts ex-
pressing antiinflammatory substance. The myoblasts were infected with a
retroviral vector carrying the expression of interleukin-1 receptor antago-
nist protein (IL-1Ra) and a neomycin-resistance gene (Bandara et al.,
1993). After infection, the myoblasts were selected using neomycin (1,000
 
m
 
g/ml of medium) to obtain nearly 100% infected cells, because nonin-
fected cells die when subjected to neomycin treatment. The selected myo-
blasts were first analyzed in vitro for their ability to express IL-1Ra (80 ng/
1 
 
3 
 
10
 
6
 
 cells 48 h after infection). The engineered myoblasts were found
capable of differentiating into myotubes
 
 
 
in vitro and forming myofibers
after intramuscular transplantation in vivo. The modified myoblasts were
subsequently infected with adenovirus carrying LacZ reporter gene ex-
pression and injected into mdx muscle. The early fate of the injected cells
was monitored and compared with that of nonengineered cells using the
protocol described below.
 
Immunohistochemistry for Desmin
 
The different muscle cell populations were fixed with methanol at 
 
2
 
20
 
8
 
C
for 1 min, followed by two rinses in PBS. The cell cultures were blocked
with 10% horse serum for 1 h and incubated with the first antibody (1/200
monoclonal mouse anti-desmin; Sigma Chemical Co., St. Louis, MO) for 1 h.
After three rinses in PBS, the sections were incubated with a second anti-
body, anti-mouse conjugated to Cy3 immunofluorescence (1/200; Sigma
Chemical Co.).
 
Myoblast Transplantation
 
Different populations of muscle cells were used for these experiments.
0.5–1 
 
3 
 
10
 
6
 
 cells were injected percutaneously into the midportion of the
hindlimb muscle for each experimental group; the experimental groups
that were compared together received the same amount of cells. Primary
mdx muscle–derived cells, myoblasts isolated from single muscle fibers,
immortalized mdx myoblasts, and IL-1Ra–expressing myoblast cultures,
were transduced with an adenovirus carrying the 
 
LacZ 
 
reporter gene us-
ing a multiplicity of infection of 50. 48 h after transduction, the different
groups of transduced myoblasts were harvested by trypsinization (0.1%
trypsin), washed in HBSS, and intramuscularly injected with a Drummond
syringe. At different time points after injection (0.5, 12, 24, 48, h, and 5 d),
the animals were killed, and the injected muscles were assayed for 
 
LacZ
 
expression (histochemistry and O-nitrophenyl-
 
b
 
-
 
d
 
-galactopyranoside
[ONPG]). The 
 
b
 
-galactosidase expression obtained from the injected
muscles was compared with the transduced cell extract before transplanta-
tion (0 h after injection). Five to six C57 BL10J mdx/mdx mice (2 mo old)
were used for each group. The experiment animals were kept in the Ran-
gos Research Center Animal Facility of Children’s Hospital of Pittsburgh.
The policies and procedures of the animal laboratory were in accordance
with those detailed in the guide for the Care and Use of Laboratory Ani-
mals published by the USA Department of Health and Human Services.
Finally, the research protocols used for these experiments were approved
by the Animal Research and Care Committee at Children’s Hospital of
Pittsburgh and the University of Pittsburgh (Protocol nos. 9–96 & 1–97).
 
LacZ Staining by Histochemical Technique
 
Cryostat sections of the injected and control muscles were stained for
LacZ expression using the following technique: the muscles were fixed
with 1.5% glutaraldehyde (Sigma Chemical Co.) for 1 min, and were
rinsed twice in PBS and incubated in X-gal substrate (0.4 mg/ml 5-bromo-
chloro-3-indolyl-
 
b
 
-
 
d
 
-galactoside [Boehringer-Mannheim, Indianapolis,
IN], 1 mM MgCl
 
2
 
, 5 mM K
 
4
 
Fe(CN)6/5 mm K
 
3
 
Fe(CN)
 
6
 
 in PBS) overnight
(37
 
8
 
C). After the LacZ histochemistry, the muscle sections were counter-
stained with hematoxylin/eosin and visualized by light microscopy (Op-
tiphot microscope; Nikon, Inc., Melville, NY).
 
Assays for 
 
b
 
-galactosidase Activities
 
This technique was performed in order to achieve a better quantitation
and comparison of the transgene expression level in the infected cells and
the injected muscles (Sambrook et al., 1989). 
 
T
 
he injected muscles or cells
were frozen in liquid nitrogen and homogenized in 0.25 M Tris-HCL (pH
7.8), and the homogenates were centrifuged at 3,500 
 
g
 
 for 5 min. The mus-
cle homogenate was disrupted by three cycles of freeze/thaw, and the su-
pernatant was recolted by centrifugation (12,000 
 
g
 
/5 min at 4
 
8
 
C) and
transferred to a microcentrifuge tube. 30 
 
m
 
l out of this extract was mixed
with 66 
 
m
 
l of 4 mg/ml ONPG (O-nitrophenyl-
 
b
 
-
 
d
 
-galactopyranoside;
Sigma Chemical Co.) dissolved in 0.1 M sodium phosphate (pH 7.5), 3 
 
m
 
l
of 4.5 M 
 
b
 
-mercaptoethanol dissolved in 0.1 M MgCl
 
2
 
, and 201 
 
m
 
l 0.1 M
sodium phosphate. The mixture was then incubated at 37
 
8
 
C for 30 min.
The reaction was stopped by adding 500 
 
m
 
l of 1 M Na
 
2
 
CO
 
3
 
, and the OD
was read on a spectrophotometer at a wavelength of 420 nm. The level of 
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b
 
-galactosidase activity (U/sample) was extrapolated on a calibration
curve that converted the OD at 420 nm to the concentration of 
 
b
 
-galac-
tosidase enzyme. We then compared the level of 
 
b
 
-galactosidase enzyme
in the transduced noninjected myoblasts with the amount obtained in the
injected muscle 0.5, 12, 24, 48 h, and 5 d after injection.
 
Immunochemical Staining for Slow Myosin Heavy 
Chain (MyHC)
 
A monoclonal antibody specific for slow myosin heavy chain (MyHC) was
used in this study. The antibody (M 8421; Sigma Chemical Co.) reacts with
the slow MyHC of adult skeletal muscle. MyHC staining was performed
using indirect immunoperoxidase techniques. In brief, 10-
 
m
 
m serial cry-
ostat sections were collected on glass slides, fixed with cold acetone
(
 
2
 
20
 
8
 
C) for 2 min., and blocked with 5% horse serum for 1 h. The sec-
tions were incubated overnight at room temperature in a humid chamber
with primary antibodies diluted 1:500 in PBS, pH 7.4, containing 4% horse
serum. The sections were subsequently rinsed three times in PBS and in-
cubated with sheep anti-mouse antibodies conjugated with horseradish
peroxidase (A7282; Sigma Chemical Co.) diluted 1:100 in PBS for 90 min.
After three rinses in PBS, the peroxidase activity was then revealed by in-
cubation with 1 mg/ ml diaminobenzidine in PBS containing 0.1% hydro-
gen peroxide (H
 
2
 
O
 
2
 
). Peroxide reaction was then revealed and stopped by
repeated rinses in PBS. Sections were mounted in GelMount (Biomeda
Corp., Foster City, CA) and observed under light microscopy (Nikon Op-
tiphot microscope). Colocalization of the LacZ and slow myosin heavy
chain expressing muscle fibers was then performed on serial muscle sec-
tions from tissue samples taken 2 and 5 d after transplantation.
 
Statistical Analysis
 
The average transduction level was computed at different time points for
each group (
 
n
 
 5
 
 5) and compared over time by one-factor ANOVA (mul-
ticomparison type factorial) using statistical software (Stat View 512;
Brain Power, Calabasas, CA).
 
Results
 
Isolation of Different Populations of Skeletal
Muscle–derived Cells
 
We have observed that different populations of primary
muscle–derived cells isolated from hindlimb muscle at dif-
ferent preplates contain a variable percentage of desmin
positive cells. The different populations of cells consist of a
mixture of muscle-derived cells, including myoblasts, fi-
broblasts, and adipocytes. We have found that populations
of muscle-derived cells display different desmin immu-
noreactivity ranging from 7 to 78% after preplate (see Fig.
1 
 
A
 
). Furthermore, we have observed that the first pre-
plate contained only 7% of desmin-positive cells, while the
sequential preplates were enriched in their content of
desmin-positive cells (2 
 
5
 
 14%; 3 
 
5
 
 25%; 4 
 
5
 
 72%; 5 
 
5
 
75%; and 6 
 
5
 
 78%).
These cell populations consequently had a variable abil-
ity to differentiate into myotubes when cultivated into a
fusion medium. The number of myotubes obtained in pre-
plates 1 (Fig. 1, 
 
B 
 
and
 
 C
 
) and 3 (Fig. 1, 
 
D 
 
and
 
 E
 
) were
much lower than in preplates 5 (Fig. 1, 
 
F 
 
and
 
 G
 
) and 6
(Fig. 1, 
 
H 
 
and
 
 I
 
). Although we observed that all preplates
showed fusion of myoblasts into myotubes, the popula-
tions of muscle-derived cells with higher numbers of
desmin-positive cells displayed a better ability to differen-
tiate into myotubes.
We have obtained 97% of desmin-positive cells from a
single myofiber isolated from EDL. In addition, the mdx
myoblast cell line, isolated from transgenic mice carrying
the SV40 T antigen, was nearly 100% desmin-positive.
These cells were also capable of differentiating into myo-
tubes, which demonstrates the high myogenicity index of
those cell cultures (not shown).
 
Characterization of the Survival of the
Different Populations of Muscle-derived Cells
After Transplantation
 
We have observed that injection of the muscle-derived
cells obtained after preplate 1 was rapidly lost 48 h after
injection; only 17% of the transgene expression present on
the injected cells before injection was measured in the in-
jected muscle (Fig. 2). However, an improvement in the
survival of the injected myoblasts was obtained with the
Figure 1. Characterization of the different populations of mus-
cle-derived cells in vitro. The populations of muscle-derived cells
after preplate (pp) displayed different desmin immunoreactivities
ranging between 7 and 78% (A). The first preplate contained
only 7% of desmin-positive cells, while the sequential preplates
were enriched in myoblast content: pp2 5 14%, pp3 5 25%, pp4 5
72%, pp5 5 75%, and pp6 5 78% (A). Moreover, the ability of
the muscle-derived cells to fuse into myotubes was found higher
in pp5 (F and G) and pp6 (H and I) in comparison with PP1 (B
and C) and PP3 (D and E). The desmin immunofluorescence is
shown in B, D, F, and H, and the corresponding phase contrast
field is shown in C, E, G, and I, respectively. Bar, 120 mm.Qu et al. Cell Survival and Myoblast Transfer Therapy 1261
subsequent preplates. The cells isolated at preplate 2 led
to a 55% myoblast loss 48 h after injection, a 12% loss at
preplate 3, and a 124% gain of the level of transgene ex-
pression present in the cells before transplantation pre-
plate 6 (Fig. 2). These observations suggested that we iso-
lated different populations of muscle-derived cells during
preplating that displayed a better survival rate after trans-
plantation.
Surprisingly, the pure population of myoblasts obtained
from the isolated myofibers (fiber myoblasts, FMb) dis-
playing over 95% desmin immunoreactivity suffered a
rapid loss after myoblast transplantation. In fact, a loss of
96% of the injected myoblasts was observed 48 h after
transplantation (Fig. 2). Similarly, the mdx myoblast cell
line (cell line) was rapidly lost after transplantation: 93%
of the level of transgene expression present in the cell cul-
ture after implantation disappeared 2 d after injection.
The high percentage of desmin-positive cells present in the
muscle-derived cell population in preplate 6, therefore,
was probably not the only factor explaining the improve-
ment of cell survival after implantation.
Even though we have isolated populations of muscle-
derived cells displaying a better survival after injection
(PP3, PP6), all the cell populations decrease in reporter
gene expression between days 2 and 5 after injection. The
cells with the better survival rate consequently retain the
better transgene expression at day 5.
Determination of the Ability of the
Different Populations of Muscle-derived
Cells to Achieve Gene Delivery in
Skeletal Muscle In Vivo
All the myoblast populations after adenoviral transduc-
tion have been found to be capable of delivering b-galac-
tosidase reporter gene to skeletal muscle 2 and 5 d after in-
fection (Fig. 3). In fact, by using the same number of cells,
we have observed that PP6, and, to a lesser extent, PP3, of-
fer better gene transfer than the population of muscle-
derived cells isolated at PP1 and PP2. The ability of the
purified muscle cells (PP6 and PP3) to circumvent the
poor survival of the injected cells may explain the better
efficiency of gene transfer in the injected muscle. How-
ever, we have observed that PP6 displays a better ability to
fuse with host myofibers (large diameter) when compared
with muscle-derived cells isolated at earlier preplates. The
myoblast cell line (cell line) and the highly pure myoblast
culture isolated from myofibers (FMb) also display a
reduction in gene transfer when compared with the
muscle-derived cells isolated at preplate 6, suggesting that
the ability of cells to bypass the poor survival after injec-
tion leads to an improvement of gene transfer to skeletal
muscle.
The Influence of Muscle Fiber Type on the Survival of 
the Muscle-derived Cells
To determine whether the origin of the muscle cells influ-
enced the cell survival after injection, we investigated the
type of LacZ-positive myofibers (fast or slow twitch myo-
fibers) formed in the injected gastrocnemius muscle (Fig.
4, E–H) by using anti-slow MyHC antibodies after FMb
and PP6 cell transplantation. We evaluated whether a
colocalization of myofibers expressing b-galactosidase and
slow myosin heavy chains occurs in the injected muscle.
After injection, the cells either fused together to form
myotubes or with host myoblasts and muscle fibers to form
mosaic myofibers. Serial sections revealed that transduced
myoblasts obtained from single myofibers either fused to-
Figure 2. Characterization of the survival of different popula-
tions of muscle-derived cells after transplantation. Injection of
the muscle-derived cells obtained after preplate 1 was rapidly lost
48 h after injection: only 17% of the transgene expression present
on the injected myoblasts before injection was measured in the
injected muscle. However, the cells isolated at preplate 2 led to
55% of the myoblast loss; preplate 3 led to a 12% loss, and pre-
plate 6 gained 124% of the level of transgene expression present
in the cells before transplantation. Surprisingly, a 96% loss of the
pure population of myoblasts isolated from single myofibers was
still observed 48 h after transplantation (fiber myoblast, FMb).
Similarly, the immortalized myoblast cell line was rapidly lost af-
ter transplantation: 93% of the level of transgene expression
present in the cell culture after implantation had disappeared 2 d
after injection (Mdx cell line). Even though PP3 and PP6 dis-
played a better cell survival 2 d after injection, a decrease was still
observed in the amount of LacZ reporter gene in the injected
muscle 5 d after injection. However, the cells that displayed a bet-
ter survival (PPs 3 and 6) remained with a higher level of gene
transfer 5 d after injection. *P , 0.05 when compared with trans-
duced noninjected myoblasts (0 h).The Journal of Cell Biology, Volume 142, 1998 1262
gether or with host myoblasts to form myotubes and im-
mature myofibers in which no slow myosin heavy chain
was detected (Fig. 4, A and B), or fused with host myofi-
bers that showed an absence of expression of slow MyHC
(Fig. 4, E and F). This result suggested that the myoblasts
from single muscle fibers may preferentially fuse with host
myofibers of the same phenotype. In contrast, the muscle-
derived cells isolated at PP6 fused with both host myofi-
bers that expressed (Fig. 4, C and D) or did not express
slow myosin heavy chain (Fig. 4, G and H), suggesting that
the muscle-derived cells at PP6 have the ability to fuse
with fast and slow muscle fibers.
Engineering of Muscle Cells that Display 
Antiinflammatory Action
In an attempt to investigate whether the cells capable of
expressing antiinflammatory substances can improve the
cell survival after injection, we genetically engineered myo-
blasts to express IL-1Ra, which is capable of competing
with inflammatory cytokine IL-1 for binding to the IL-1
receptor, but does not induce IL-1 receptor signaling. We
then compared the engineered myoblast survival with the
nonengineered control cells (Fig. 5). The myoblast used
for this experiment, the mdx cell line, displayed a drastic
loss of the injected cells after injection (Fig. 2). Here, we
again observed an 84% loss of the control myoblasts, non-
Figure 3. Determination of the ability of the different popula-
tions of muscle-derived cells to achieve gene transfer in muscle 2
and 5 d after injection. The population of purified primary myo-
blasts pp6 and, to a lesser extent, pp3, offered a better gene trans-
fer than the population of muscle-derived cells isolated in pp1
and pp2. The myoblast cell line (cell line) and the highly pure my-
oblast culture isolated from fast single myofibers (FMb) also dis-
played a reduction in gene transfer when compared with the mus-
cle-derived cells isolated in pp6. Bar, 50 mm. 
Figure 4. Expression of slow MyHC in LacZ-positive cells in so-
leus (slow) and gastrocnemius (fast) muscles 5 d after FMb (A, B,
E, F) and PP6 (C, D, G, H) implantation. Serial cryostat sections
were used to reveal the colocalization of LacZ-expressing myofi-
bers with the presence of myofibers expressing slow MyHC. The
transduced myoblasts isolated from single myofibers (FMb) ei-
ther fused together or with host myoblasts and formed immature
myofibers in which no slow myosin heavy chain was detected (*,
A and B), or fused with host myofibers that similarily did not ex-
press slow MyHC (*, E and F). This result suggested that the myo-
blasts from fast single fibers did not fuse with myofibers express-
ing slow MyHC (#, A and B) and may preferentially have fused
with host muscle fibers of the same phenotype. In contrast, pre-
plate 6 fused with host muscle fibers expressing (#, C and D) or
not expressing slow myosin heavy chain (*, C, D, G, and H), sug-
gesting that the muscle derived cells at PP6 had the ability to fuse
with both fast- and slow-twitch muscle fibers. Bar, 50 mm.Qu et al. Cell Survival and Myoblast Transfer Therapy 1263
engineered cells (Fig. 5 A) by 48 h after injection by the
significant decrease in the amount of b-galactosidase ex-
pression in comparison to the noninjected transduced myo-
blast at 0 h. Moreover, a slight increase in the amount of
reporter gene was detected at 120 h after injection, which
remains significantly lower than that observed in control
cells.
The cells engineered to express IL-1Ra, though, signifi-
cantly reduced early loss of the injected cells 48 h after in-
jection. Although we observed a major loss of 60% in the
amount of b-galactosidase expressed in the noninjected
cells (P , 0.05) 24 h after injection, the level of b-galac-
tosidase expression detected 2 d after injection was not
found to be significantly different than in the noninjected
IL-1Ra–expressing myoblasts (Fig. 5 B). Moreover, the
level of gene transfer did not change significantly between
2 and 5 d after injection, and still remained nondifferent to
that observed in the noninjected myoblasts. (Fig. 5, B–D).
This observation suggests that inflammation also plays a
role in the poor survival rate of the injected cells; conse-
quently, approaches capable of blocking the inflammation
may aid in the development of strategies to achieve effi-
cient myoblast transplantation.
Discussion
Several approaches have been investigated for efficient
gene delivery to skeletal muscle, but all suffer from signifi-
cant problems. Myoblast transplantation remains limited
by the immune responses, poor survival rate of the in-
jected myoblasts, and low spread of the injected cells that
remain located in the vicinity of the injection site. Gene
therapy in muscle has been hindered by the immunogenic-
ity/cytotoxicity of the viral vectors and the differential
transduction with viral vectors throughout the maturation
of muscle fibers.
While the construction of viral vectors capable of deliv-
ering and expressing the full-length dystrophin into dys-
trophin-deficient muscle cells with perhaps little cytotoxic-
ity and immunogenicity is being achieved, the incapacity
of viral transduction in mature muscle fibers still remains.
Even though multiple strategies, including induction of
muscle regeneration and fenestration of the basal lamina,
are under investigation to improve viral transduction in
mature muscle (van Deutekom et al., 1998a; van Deu-
tekom et al., 1998b), we have recently observed that the ex
vivo gene transfer approach can help to improve viral en-
try and transduction in mature myofibers.
The ex vivo procedure was originally used to verify the
success of myoblast transplantation without immunologi-
cal problems. This method was performed using adenovi-
rus, retrovirus, and herpes simplex virus carrying the ex-
pression of reporter genes (b-galactosidase or luciferase).
It showed that transduced myoblasts (isogenic myoblasts)
fused and reintroduced the reporter genes into the in-
Figure 5. Characterization
of the ability of engineered
myoblast expressing antiin-
flammatory substance to re-
duce the poor survival of the
injected cells. The survival of
the myoblasts engineered to
express IL-1Ra was com-
pared with the nonengi-
neered control cells. The
nonengineered cells were
rapidly lost 48 h after injec-
tion (Control myoblast). In
contrast, the cells engineered
to express IL-1Ra signifi-
cantly reduced the early loss
of the injected cells (IL-1Ra–
expressing myoblast): only
20% of the injected cells
seemed to be lost 48 h after
injection. However, a signifi-
cant reduction in the amount
of  b-galactosidase expres-
sion was observed 24 h after
injection in comparison to
the noninjected myoblasts.
We observed a high number
of transduced myofibers that
persisted between day 2 and
day 5 after injection of the
IL-1Ra expressing myoblasts
(C and D). The absence of
significant difference for both populations of cells at 0 and 0.5 h after injection suggested that the loss of myoblasts was minimal during
injection. *P , 0.05 when compared with transduced noninjected myoblasts (0 h). Bar, 50 mm.The Journal of Cell Biology, Volume 142, 1998 1264
jected muscle (Salvatori et al., 1993; Huard et al., 1994c;
Rando and Blau, 1994; Booth et al., 1997; Floyd et al.,
1997; Floyd et al., 1998; van Deutekom et al., 1998a; van
Deutekom et al., 1998b). Recently we observed that the ex
vivo approach could be used as an alternative to improve
the efficiency of viral vectors in mature muscle. In fact, the
ex vivo gene transfer approach of adenovirus, retrovirus,
and herpes simplex virus resulted in a higher efficiency of
gene delivery than that observed by direct injection of the
same number of viral particles (Booth et al., 1997; Floyd
et al., 1997; Floyd et al., 1998; van Deutekom et al., 1998a;
van Deutekom et al., 1998b). The ability of these viral vec-
tors to transduce myoblasts efficiently make the ex vivo
approach an important alternative for viral gene delivery
to skeletal muscle.
The well-documented poor survival of the injected myo-
blasts, however, limits the efficiency of myoblast-mediated
ex vivo gene transfer to mature muscle. It has been ob-
served that many of these injected myoblasts were rapidly
lost within 48 h after transplantation (Huard et al., 1994c;
Beauchamps et al., 1994; Fan et al., 1996). Even though
the causes of the poor survival rate of the injected myo-
blast after implantation remain unclear, the accelerated
death of the injected myoblasts has been shown to be
partly related to the inflammation (Guerette et al., 1997;
Tremblay et al., 1997; Merly et al., 1998).
The present investigation has been performed in order
to characterize whether inflammation is the only factor in-
volved in the poor survival of the injected myoblast. Ad-
vances in cellular and molecular biology have identified
IL-1Ra and soluble receptors for tumor necrosis factor-a
as promising proteins to inhibit the inflammation and the
progression of arthritis (Doherty, 1995; Bandara et al.,
1993). The extremely wide range of biological activities of
IL-1Ra may improve cell survival by blocking the action of
an inflammatory cytokine (IL-1). We have then engi-
neered myoblasts capable of expressing antiinflammatory
substances such as IL-1Ra, and tested the ability of these
engineered cells to prevent the rapid loss of the injected
cells.
We have observed that engineered myoblasts expressing
IL-1Ra allow for a better survival rate of the injected myo-
blasts 48 h after injection (Fig. 5). The nonengineered myo-
blast cell line has displayed poor survival of the injected
cells, but the same cell line expressing IL-1Ra has signifi-
cantly improved the survival rate of the injected cells 48 h
after injection. We have observed a major improvement in
the survival of the injected cells 48 h after injection by a lo-
cal expression of an antiinflammatory substance, even if
the amount of the b-galactosidase reporter gene decreased
at 24 h in comparison to the 0 h. The result suggests that
IL-1Ra–expressing myoblasts have probably fused be-
tween 24 and 48 h after injection, and have led to an in-
crease of the expression of b-galactosidase reporter gene.
However, we have observed a slight decrease in the
amount of b-galactosidase reporter gene expression at 5 d
after injection, which may be related to the immune rejec-
tion problem (see below).
Inflammation does not likely stand as the only factor in-
volved in the rapid loss of the injected myoblasts after im-
plantation. In fact, an improvement in the survival rate of
the injected myoblasts has been obtained through the use
of antiinflammatory drugs (anti-LFA-1), but a reduced
loss of the injected myoblasts still remains (Guerette et al.,
1997; Tremblay et al., 1997). Similarly, in this study, a sub-
stantial reduction in the loss of the injected myoblasts has
been achieved with the IL-1Ra–expressing cells, but z20%
loss is still observed 48 h after injection.
We have then evaluated whether the use of different
populations of muscle-derived cells can help to circumvent
the poor survival of the injected myoblasts after transplan-
tation. To evaluate this hypothesis, mdx myoblast cell
lines, pure myoblasts isolated from single myofibers, and
different populations of primary muscle–derived cells
have been injected into adult mdx muscle. The myoblasts
have been adenovirally transduced, and the early fate of
the injected cells after injection has been evaluated at dif-
ferent time points after injection (0.5, 12, 24, 48 h, and 5 d).
We have observed that populations of primary muscle–
derived cell cultures isolated from hindlimb muscle dis-
played a differential ability to express desmin and differ-
entiate into myotubes, as well as a completely different
cell survival after injection. The same number of muscle
cells derived from preplate 1 vs. preplate 6 has resulted,
respectively, in 83% loss and 124% gain in the transgene
expression by 2 d in comparison to the noninjected trans-
duced cells at 0 h. This observation suggests that the mus-
cle-derived cells PP6 have totally overcome the rapid loss
of the injected cells without the requirement of blocking
the inflammation.
The content of desmin-positive cells could be involved
with the ability of the purified muscle cells (preplate 6) to
display a better survival rate than the cell population con-
taining fewer desmin-positive cells. Even though this can
stand as a likely explanation, especially between PP1 and
PP6, the poor survival of pure cultures of myoblasts iso-
lated from single fibers and the myoblast cell line, which
both exhibited a nearly 100% desmin immunoreactivity,
shows that the number of desmin-positive cells is not the
only factor involved in the poor survival of the injected
cells.
We have attempted to characterize whether the source
of muscle-derived cells may have a primordial role in the
early survival of the injected myoblasts. A great difference
in the content of satellite cells has already been observed
between slow and fast twitch muscles (Schmalbruch and
Hellhammer, 1977; Kelly, 1978; Gibson and Schultz, 1982).
The type of satellite cells isolated from these muscles may
also possibly display a differential fate after transplanta-
tion. In fact, it has been reported that transplantation of
L6 rat myoblasts expressing type II myosin heavy chain
isoform (MyHCs) in vitro predominantly fuse together
into myotubes or with host myofibers expressing the same
myosin isoform (Pin et al., 1997). In contrast, a very low
percentage of these L6 myoblasts have been found capa-
ble of fusing with myofibers expressing slow MyHC (type
1) when injected into soleus, plantaris, and medial gastroc-
nemius (Pin et al., 1997). Although C2C12 and cloned satel-
lite cells have been found capable of fusing with all fiber
types encountered (Hughes and Blau, 1992), both popula-
tions of cells have been capable of expressing both fast and
slow MyHCs in vitro, and may represent a population of
multipotential myoblast stem cells (Edom et al., 1994;
MacIntyre and Merrifield, 1997).Qu et al. Cell Survival and Myoblast Transfer Therapy 1265
We have observed that the PP6 muscle-derived cells
have the ability to fuse with myofibers expressing both the
slow and fast myosin isoforms in contrast to myoblasts ob-
tained from isolated single myofibers, which either fused
together or with host myofibers showing the absence of
slow MyHC (see Fig. 4). The inability of myoblasts ob-
tained from isolated single myofibers to fuse with myofi-
bers expressing slow MyHC may be involved in the differ-
ential survival of the injected myoblasts, since the injected
muscle (gastrocnemius and soleus) contains a mixture of
myofibers expressing fast and slow myosin isoforms. The
injected myoblasts that are less able to fuse with some spe-
cific types of host myofibers will likely display a poor sur-
vival at the injection site. These results suggest that the
types of injected myoblasts and host muscle fibers (type 1
or 2) may represent a major determinant in the cell sur-
vival after transplantation.
Similarly, all the myotubes formed by the fusion of mdx
cell line myoblasts in the injected muscle exhibited slow
MyHC (not illustrated). However, the mdx cell line was
found incapable of efficiently fusing with host myofibers
expressing slow or fast MyCHs. The inability of some pop-
ulations of myoblast to fuse efficiently with host myofibers
may represent another factor involved in the poor survival
of the injected cells.
Finally, it is unlikely that the poor survival of the in-
jected cells (fiber myoblast, mdx myoblast cell line, and
early preplate, PP1 and PP2), is due to inflammation and
immune rejection related to the first generation adenovi-
rus, since in some myoblast populations (PP6) the cells
were infected with the same version of adenovirus and dis-
played a complete cell survival after injection. Further-
more, a similar poor survival of the injected myoblasts (48 h
after injection) have been described by other research
groups that were not using a first-generation adenovirus as
a marker to follow the early fate of the injected cells
(Beauchamps et al., 1994; Fan et al., 1996; Guerrette et al.,
1997).
Even though different populations of muscle-derived
cells and the IL-1Ra–expressing myoblasts display a better
survival after implantation in skeletal muscle (48 h), long-
term persistence of the injected cells appears to be hin-
dered by immune responses. We have observed that most
of the muscle cell populations display a reduction in the
amount of b-galactosidase expression between days 2 and
5 after injection (see Fig. 2). Furthermore, we have ob-
served that the number of LacZ-expressing myofibers
decreases over time in the injected muscle, even when IL-
1Ra–expressing myoblasts are used. We have further in-
vestigated this issue and observed an infiltration of CD41-
and CD81- activated lymphocytes in the injected muscle
that colocalize with the transduced myofibers, showing
that engineered myoblasts still trigger an immune re-
sponse (not illustrated). The presence of immune re-
sponses against adenovirally transduced allogenic myo-
blasts has already been described (Floyd et al., 1997; Floyd
et al., 1998). We are, consequently, investigating whether
engineering specific populations of muscle-derived cells
with immunosuppressive substances may prevent both the
poor survival and the immune response related to myo-
blast transfer.
In conclusion, the development of approaches to im-
prove cell survival after myoblast transfer may improve
both the success of myoblast transplantation and the ex
vivo gene transfer mediated by myoblasts. Since the ex
vivo gene transfer has been capable of improving the effi-
ciency of viral gene transfer to mature skeletal muscle, the
development of an approach to enhance the survival of the
injected myoblast will further improve the delivery of viral
vectors in mature myofibers. This study should help in the
development of strategies based on cell and gene therapy
to efficiently deliver genes for inherited diseases such as
Duchenne Muscular Dystrophy, and for treating inade-
quate and deficient muscle healing after muscle injuries.
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